Pandemic Preparedness Funding, Influenza Preparedness; COVID-19 Response and Therapeutics Procurement and Distribution; FY 2024 Labor-HHS Appropriations; Pandemic and All-Hazards Preparedness Act Reauthorization
Pandemic Preparedness; Biomanufacturing
Inflation Reduction Act Rx Provisions Implementation; S. 476, Maintaining Investments in New Innovation Act
S. 866, American Innovation and Jobs Act; H.R. 2673, American Innovation and R&D Competitiveness Act; H.R. 3938, Build It In America Act
COVID-19 Trade Related Aspects of Intellectual Property Rights Waiver
Duration: July 19, 2021
to
November 2, 2023
General Issues: Health Issues , Science/Technology , Medicare/Medicaid , Taxation/Internal Revenue Code , Trade (Domestic & Foreign)
Spending: about $1,400,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2021: U.S. Senate, House of Representatives, Office of Science & Technology Policy (OSTP), Health & Human Services - Dept of (HHS), Centers For Disease Control & Prevention (CDC), Natl Institutes of Health (NIH), Centers For Medicare and Medicaid Services (CMS), White House Office, Natl Security Council (NSC), U.S. International Trade Commission (ITC)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Doug Stoss
Cong. John Shadegg - Legislative Assistant, Subcommittee Staff Director, Chief of Staff, Policy Director; Centers for Medicare and Medicaid Services - Senior Counselor, Chief of Staff
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
4th Quarter, 2023
VIR BIOTECHNOLOGY, INC. in-house lobbying effort was terminated on Nov. 3, 2023
Original Filing: 301518379.xml
Lobbying Issues
Pandemic Preparedness Funding, Influenza Preparedness; COVID-19 Response and Therapeutics Procurement and Distribution; FY 2024 Labor-HHS Appropriations; Pandemic and All-Hazards Preparedness Act Reauthorization
Agencies Lobbied
U.S. Senate U.S. House of Representatives Office of Science & Technology Policy (OSTP) Health & Human Services - Dept of (HHS) Centers For Disease Control & Prevention (CDC)
Lobbying Issues
Pandemic Preparedness; Biomanufacturing
Agencies Lobbied
U.S. Senate U.S. House of Representatives Office of Science & Technology Policy (OSTP) Health & Human Services - Dept of (HHS) Natl Institutes of Health (NIH)
Lobbying Issues
Inflation Reduction Act Rx Provisions Implementation; S. 476, Maintaining Investments in New Innovation Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
S. 866, American Innovation and Jobs Act; H.R. 2673, American Innovation and R&D Competitiveness Act; H.R. 3938, Build It In America Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
COVID-19 Trade Related Aspects of Intellectual Property Rights Waiver
Agencies Lobbied
U.S. House of Representatives U.S. Senate White House Office Natl Security Council (NSC) U.S. International Trade Commission (ITC)
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2023
In Q3, VIR BIOTECHNOLOGY, INC. had in-house lobbyists. The report was filed on Oct. 20, 2023.
Original Filing: 301511645.xml
Lobbying Issues
Pandemic Preparedness Funding, Influenza Preparedness; COVID-19 Response and Therapeutics Procurement and Distribution; FY 2024 Labor-HHS Appropriations; Pandemic and All-Hazards Preparedness Act Reauthorization
Agencies Lobbied
U.S. Senate U.S. House of Representatives Office of Science & Technology Policy (OSTP) Health & Human Services - Dept of (HHS) Centers For Disease Control & Prevention (CDC)
Lobbying Issues
Pandemic Preparedness; Biomanufacturing
Agencies Lobbied
U.S. Senate U.S. House of Representatives Office of Science & Technology Policy (OSTP) Health & Human Services - Dept of (HHS) Natl Institutes of Health (NIH)
Lobbying Issues
Inflation Reduction Act Rx Provisions Implementation; S. 476, Maintaining Investments in New Innovation Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
S. 866, American Innovation and Jobs Act; H.R. 2673, American Innovation and R&D Competitiveness Act; H.R. 3938, Build It In America Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
COVID-19 Trade Related Aspects of Intellectual Property Rights Waiver
Agencies Lobbied
U.S. House of Representatives U.S. Senate White House Office Natl Security Council (NSC) U.S. International Trade Commission (ITC)
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2023
In Q2, VIR BIOTECHNOLOGY, INC. had in-house lobbyists. The report was filed on July 20, 2023.
Original Filing: 301487672.xml
Lobbying Issues
Pandemic Preparedness Funding, Influenza Preparedness; COVID-19 Response and Therapeutics Procurement and Distribution; FY 2024 Labor-HHS Appropriations; Pandemic and All-Hazards Preparedness Act Reauthorization
Agencies Lobbied
U.S. Senate U.S. House of Representatives Office of Science & Technology Policy (OSTP) Health & Human Services - Dept of (HHS) Centers For Disease Control & Prevention (CDC)
Lobbying Issues
Pandemic Preparedness; Biomanufacturing
Agencies Lobbied
U.S. Senate U.S. House of Representatives Office of Science & Technology Policy (OSTP) Health & Human Services - Dept of (HHS) Natl Institutes of Health (NIH)
Lobbying Issues
Inflation Reduction Act Rx Provisions Implementation
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
S. 866, American Innovation and Jobs Act; H.R. 2673, American Innovation and R&D Competitiveness Act; H.R. 3938, Build It In America Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
COVID-19 Trade Related Aspects of Intellectual Property Rights Waiver
Agencies Lobbied
U.S. House of Representatives U.S. Senate White House Office Natl Security Council (NSC) U.S. International Trade Commission (ITC)
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2023
In Q1, VIR BIOTECHNOLOGY, INC. had in-house lobbyists. The report was filed on April 20, 2023.
Original Filing: 301463547.xml
Lobbying Issues
Pandemic Preparedness Funding, Influenza Preparedness; COVID-19 Response and Therapeutics Procurement and Distribution; FY 2024 Labor-HHS Appropriations; Pandemic and All-Hazards Preparedness Act Reauthorization
Agencies Lobbied
U.S. Senate U.S. House of Representatives Office of Science & Technology Policy (OSTP) Health & Human Services - Dept of (HHS) Centers For Disease Control & Prevention (CDC)
Lobbying Issues
Emergency Clinical Trials Policy; Pandemic Preparedness; Biomanufacturing
Agencies Lobbied
U.S. Senate U.S. House of Representatives Office of Science & Technology Policy (OSTP) Health & Human Services - Dept of (HHS) Natl Institutes of Health (NIH)
Lobbying Issues
Inflation Reduction Act Rx Provisions Implementation
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
S. 866, American Innovation and Jobs Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
COVID-19 Trade Related Aspects of Intellectual Property Rights Waiver
Agencies Lobbied
U.S. House of Representatives U.S. Senate White House Office Natl Security Council (NSC) U.S. International Trade Commission (ITC)
Type of Issue
Trade (Domestic & Foreign)
4th Quarter, 2022
In Q4, VIR BIOTECHNOLOGY, INC. had in-house lobbyists. The report was filed on Jan. 20, 2023.
Original Filing: 301439608.xml
Lobbying Issues
S. 3799 PREVENT Pandemics Act; Pandemic Preparedness Funding; COVID-19 Response and COVID-19 Therapeutics Procurement; S. 2640 Disease X Act; S. 3258/H.R. 6025 Flu Vaccine Act; H.R. 2617, Consolidated Appropriations Act for FY 2023
Agencies Lobbied
U.S. Senate U.S. House of Representatives Office of Science & Technology Policy (OSTP) Health & Human Services - Dept of (HHS)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Office of Science & Technology Policy (OSTP) Health & Human Services - Dept of (HHS) Natl Institutes of Health (NIH)
Lobbying Issues
Coverage and Reimbursement of COVID-19 Therapeutics.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
H.R. 7410, American-Made Medicine Act; H.R. 7505, More Cures Act; Section 174 R&D Expensing; H.R. 1304, American Innovation and R&D Competitiveness Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2022
In Q3, VIR BIOTECHNOLOGY, INC. had in-house lobbyists. The report was filed on Oct. 20, 2022.
Original Filing: 301415333.xml
Lobbying Issues
S. 3799 PREVENT Pandemics Act; Pandemic Preparedness Funding; COVID-19 Response and COVID-19 Therapeutics Procurement; S. 2640 Disease X Act; S. 3258/H.R. 6025 Flu Vaccine Act; FY 2023 Labor-HHS Appropriations; H.R. 5376, Inflation Reduction Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Office of Science & Technology Policy (OSTP) Health & Human Services - Dept of (HHS)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Office of Science & Technology Policy (OSTP) Health & Human Services - Dept of (HHS) Natl Institutes of Health (NIH)
Lobbying Issues
Coverage and Reimbursement of COVID-19 Therapeutics.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
H.R. 7410, American-Made Medicine Act; H.R. 7505, More Cures Act; Section 174 R&D Expensing; H.R. 1304, American Innovation and R&D Competitiveness Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2022
In Q2, VIR BIOTECHNOLOGY, INC. had in-house lobbyists. The report was filed on July 20, 2022.
Original Filing: 301389500.xml
Lobbying Issues
S. 3799 PREVENT Pandemics Act; Pandemic Preparedness Funding; COVID-19 Response and COVID-19 Therapeutics Procurement; S. 2640 Disease X Act; S. 3258/H.R. 6025 Flu Vaccine Act; FY 2023 Labor-HHS Appropriations.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Office of Science & Technology Policy (OSTP) Health & Human Services - Dept of (HHS)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Office of Science & Technology Policy (OSTP) Health & Human Services - Dept of (HHS) Natl Institutes of Health (NIH)
Lobbying Issues
Coverage and Reimbursement of COVID-19 Therapeutics.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
H.R. 7410, American-Made Medicine Act; H.R. 7505, More Cures Act; Section 174 R&D Expensing
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2022
In Q1, VIR BIOTECHNOLOGY, INC. had in-house lobbyists. The report was filed on April 20, 2022.
Original Filing: 301364986.xml
Lobbying Issues
S. 3799 PREVENT Pandemics Act; H.R. 2471 Consolidated Appropriations Act, COVID Supplemental Appropriations Act; Pandemic Preparedness Funding; COVID-19 Response and COVID-9 Therapeutics Procurement; S. 2640 Disease X Act; S. 3258/H.R. 6025 Flu Vaccine Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Office of Science & Technology Policy (OSTP) Health & Human Services - Dept of (HHS)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Office of Science & Technology Policy (OSTP) Health & Human Services - Dept of (HHS) Natl Institutes of Health (NIH)
Lobbying Issues
Reimbursement of COVID-19 Therapeutics
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
4th Quarter, 2021
In Q4, VIR BIOTECHNOLOGY, INC. had in-house lobbyists. The report was filed on Jan. 20, 2022.
Original Filing: 301332912.xml
Lobbying Issues
S. 2640, Disease X Act; S. 3258/H.R 6025, Flu Vaccine Act; Build Back Better - Prescription Drug Policy, Pandemic Preparedness Funding; COVID-19 Response and COVID-19 Therapeutics Procurements; Pandemic Preparedness.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Office of Science & Technology Policy (OSTP) Health & Human Services - Dept of (HHS)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Office of Science & Technology Policy (OSTP) Health & Human Services - Dept of (HHS) Natl Institutes of Health (NIH)
Lobbying Issues
Reimbursement of COVID-19 Therapeutics
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
3rd Quarter, 2021
In Q3, VIR BIOTECHNOLOGY, INC. had in-house lobbyists. The report was filed on Oct. 20, 2021.
Original Filing: 301307605.xml
Lobbying Issues
S. 2640, Disease X Act; H.Res. 601, FY 2022 Budget Resolution and Reconciliation Instructions, S. Con. Res. 14 FY 2022 Budget Resolution and Reconciliation Instructions; Prescription Policy in Budget Reconciliation; American Rescue Plan Implementation (COVID-19 Response and COVID Therapeutics Procurements), Pandemic Preparedness.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Office of Science & Technology Policy (OSTP) Health & Human Services - Dept of (HHS)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Office of Science & Technology Policy (OSTP)
Lobbying Issues
Reimbursement of COVID-19 Therapeutics
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
3rd Quarter, 2021
VIR BIOTECHNOLOGY, INC. filed a lobbying registration on Aug. 25, 2021 for in-house lobbying efforts, effective July 19, 2021.
Original Filing: 301294705.xml
Issue(s) they said they’d lobby about: BARDA/DoD Procurements, COVID-19 Response, Pandemic Preparedness, Rx Policy in Budget Reconciliation .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate